

Mayo Clinic Updates in CAR-T Cell Therapy 2021 -  
LIVESTREAM  
August 26-27, 2021

# WELCOME

Greetings,

On behalf of course directors Saad Kenderian, M.D. and Yi Lin, M.D., Ph.D., and the Mayo Clinic School of Continuous Professional Development we are pleased to announce this year's **Updates in CAR-T Cell Therapy 2021** course held via livestream, August 26-27, 2021.

## Course Description

Immunotherapy is a rapidly evolving and growing field that has broad reaching impacts on the practice of medicine. This two-day course designed to teach participants about CAR-T cell therapy, future directions in CAR-T cell therapy and cellular therapeutics, and practical management of patients receiving CAR-T cell therapy.

## Target Audience

This course is designed for physicians, physician assistants, nurses, nurse practitioners, residents, fellows, pharmacists, and allied health professionals.

## Exhibit Information

Mayo Clinic recognizes these types of educational programs would not be possible without your support. We invite you to participate in this livestream educational activity with a virtual exhibit in the amount of \$1,500. If you are interested in participating in this course, please click [here](#).

We look forward to the success of our Updates in CAR-T Cell Therapy 2021 course! If you have any questions please feel free to contact us.

Sincerely,

Aliesha Bechly  
CME Specialist  
Mayo Clinic School of Continuous Professional Development

Kris Jones  
Education Administration Coordinator  
Mayo Clinic School of Continuous Professional Development  
200 First Street SW  
Rochester, MN 55905  
Phone: 507-266-3071 E-mail: [jones.kristen@mayo.edu](mailto:jones.kristen@mayo.edu)

# WHY EXHIBIT IN OUR VIRTUAL HALL?

As many in-person national conferences and training events are being canceled and postponed, Mayo Clinic's Virtual Exhibit Hall provides companies with an innovative way to highlight your offerings to potential customers – without travel expenses, shipping of booths/materials, set-ups, or required staff.


Open 24/7 for one year for attendees, the Virtual Exhibit Hall maximizes your visibility, while providing unique customization of your messaging. You can showcase your products/services, share company videos and podcasts, provide informational brochures, photos and literature, and offer access to your key organization contacts and website links.

## Exhibitor Benefits

- Virtual Exhibit Hall promotion before, during and after conference- the content will be available to attendees for one year post-activity.
- Listing in Exhibitor Directory with link to company website & Landing Page- listing will be alphabetical
- Exhibit Booth Customization, options include PowerPoint slide, PDF handout, or video
- Two non-CME conference access links for representatives to attend all sessions.
- 90 days post-activity, exhibitors will be provided analytics on page traffic
- Attendee list (full name and company name) one week prior to the conference
- Vendor Recognition in course syllabus, opening/closing remarks, and break times

Mayo Clinic - Exhibitor


[Virtual Exhibit Hall Home](#)



**Mayo Clinic**  
**Rochester, MN**

Contact Information:

Exhibitor Name  
Email  
Phone  
Company Website



Where Healing Begins: The Mayo Clinic...

Watch later Share

**Mayo Clinic Mission and Values**

**Mission**

To inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research.

**Primary value**

The needs of the patient come first.

**Value statements**

These values, which guide Mayo Clinic's mission to this day, are an expression of the vision and intent of our founders, the original Mayo physicians and the Sisters of Saint Francis.

**Respect**

Treat everyone in our diverse community, including patients, their families and colleagues, with dignity.

**Integrity**

Adhere to the highest standards of professionalism, ethics and personal responsibility, worthy of the trust our patients place in us.

**Compassion**

Provide the best care, treating patients and family members with sensitivity and empathy.

## Sample Booth

# Mayo Clinic Updates in CAR-T Cell Therapy 2021 – LIVESTREAM

August 26 – 27, 2021

*Central Time Zone*

**Thursday, August 26, 2021**

## General Session

<b>9:50am</b>	Opening Remarks / Welcome <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i>
<b>10:00am</b>	B-Cell Acute Lymphoblastic Leukemia <i>Nirali N. Shah, M.D., M.H.Sc., NIH (Clinical Trials/Research)</i> <i>Noelle Frey, M.D., M.S., U Penn (Real World Practice)</i>
<b>10:45 am</b>	Non-Hodgkin's Lymphoma <i>Tanya Siddiqi, M.D., City of Hope (Clinical Trials/Research)</i> <i>Sattva S. Neelapu, M.D., MD Anderson Cancer Center (Real World Practice)</i>
<b>11:30am</b>	Multiple Myeloma <i>Nina Shah, M.D., University of California San Francisco</i>
<b>12:00pm</b>	<b>Break</b>
<b>12:30pm</b>	Toxicity – CRS/ICANS <i>Jae Park, M.D., Memorial Sloan Kettering Cancer Center or Cameron Turtle</i>
<b>1:00pm</b>	TBD <i>Keynote speaker: Carl H. June, M.D., U Penn</i>
<b>1:45pm</b>	Challenges of CAR-T and COVID-19 <i>Hemant S. Murthy, M.D.</i>
<b>2:15pm</b>	Wrap-Up/Closing Remarks – reminders about the next day's session
<b>2:30pm</b>	<i>Adjourn</i>

**Friday, August 27, 2021**

## Concurrent Sessions

### #1 – Clinical Research

<b>9:50am</b>	Day 2 Opening Remarks / Welcome <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i>
<b>10:00am</b>	T-cell Lymphoma: CD5, CD7 <i>LaQuisa Hill, MD, M.D., Baylor College of Medicine</i>
<b>10:30am</b>	CD30 CART <i>Barbara Savoldo, M.D., Ph.D., UNC School of Medicine</i>
<b>11:00am</b>	GBM CART <i>Christine Brown, Ph.D., City of Hope</i>
<b>11:30am</b>	Other CART Innovations <i>Hong Qin, M.D., Ph.D.</i>
<b>12:00pm</b>	<b>Break</b>
<b>12:30pm</b>	iPSC and other Off-the-Shelf IEC Platforms

	<i>Januario E. Castro, M.D., Mayo Clinic Arizona</i>
<b>1:00pm</b>	CAR-NK <i>May Daher, ??</i>
<b>1:30pm</b>	UCART <i>Reuben Benjamin, UCL</i>
<b>2:00 pm</b>	<b>Break</b> (as we transition to general session)
<b>#2 – Immune Effector Cell Program Administration – Group Discussions</b>	
<b>9:50am</b>	Day 2 Opening Remarks / Welcome <i>Eapen K. Jacob, M.D. and Matthew A. Hathcock</i>
<b>10:00am</b>	CIBMTR and Regulatory Reporting <i>Matthew A. Hathcock</i>
<b>10:30am</b>	FACT IEC Program New Standards and Virtual Inspections <i>Eapen K. Jacob, M.D.</i>
<b>11:00am</b>	Working with a Commercial Manufacturer <i>Alexis A. Jackson, M.S.</i>
<b>11:30am</b>	Industry Manufacturer and FDA Approved Therapies <i>Gina M. Lange, R.N.</i>
<b>12:00pm</b>	<b>Break</b>
<b>12:30pm</b>	Logistics of Clinical Trials <i>Jared L. Bruggeman, CCRP</i>
<b>1:15pm</b>	Coordinating Institutional Resources for Commercial and In-house Manufactured Products <i>Hollie L. Benson and Michael P. Gustafson, Ph.D.</i>
<b>2:00pm</b>	<b>Break</b> (as we transition to general session)
<b>#3 – Immune Effector Cell Program Provider Team – Group Discussions</b>	
<b>9:50am</b>	Day 2 Opening Remarks / Welcome <i>Urshila Durani, M.D., M.P.H. and Megan T. Spsychalla, P.A.-C.</i>
<b>10:00am</b>	Case Studies: <i>Allison (Alli) L. McClanahan, APRN, C.N.P.</i>
<b>10:45am</b>	Outpatient Practice <i>Megan T. Spsychalla, P.A.-C.</i>
<b>11:15am</b>	Supportive Management <i>Adrienne N. Nedved, Pharm.D., R.Ph. or Jason N. Barreto, Pharm.D.</i>
<b>11:45am</b>	Complications <i>Adrienne N. Nedved, Pharm.D., R.Ph. or Jason N. Barreto, Pharm.D.</i>
<b>12:15pm</b>	<b>Break</b>
<b>12:45pm</b>	Long-term Follow Up <i>Urshila Durani, M.D., M.P.H.</i>
<b>1:15pm</b>	Grant + Housing Resources <i>Emily R. Blackmer, M.S.W.</i>
<b>2:00pm</b>	<b>Break</b> (transition to general session)
<b>2:15pm</b>	Breakout Session Recap (15 min. each, we can make is 20 if needed) <ul style="list-style-type: none"> <li>• #1 – MD, Ph. D, Research Focused</li> <li>• #2 – Immune Effector Cell Program Administration</li> <li>• #3 – Immune Effector Cell Program Provider Team</li> </ul>
<b>3:00pm</b>	Course Wrap-Up
<b>3:15pm</b>	<b>Adjourn</b>



# Request for Taxpayer Identification Number and Certification

Give Form to the  
requester. Do not  
send to the IRS.

► Go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9) for instructions and the latest information.

Print or type.  
See Specific Instructions on page 3.

1 Name (as shown on your income tax return). Name is required on this line; do not leave this line blank. <b>Mayo Clinic</b>		
2 Business name/disregarded entity name, if different from above		
3 Check appropriate box for federal tax classification of the person whose name is entered on line 1. Check only <b>one</b> of the following seven boxes.  <input type="checkbox"/> Individual/sole proprietor or single-member LLC  <input type="checkbox"/> Limited liability company. Enter the tax classification (C=C corporation, S=S corporation, P=Partnership) ► _____ <b>Note:</b> Check the appropriate box in the line above for the tax classification of the single-member owner. Do not check LLC if the LLC is classified as a single-member LLC that is disregarded from the owner unless the owner of the LLC is another LLC that is <b>not</b> disregarded from the owner for U.S. federal tax purposes. Otherwise, a single-member LLC that is disregarded from the owner should check the appropriate box for the tax classification of its owner.  <input checked="" type="checkbox"/> Other (see instructions) ► <b>501 (c) (3) tax-exempt nonprofit corporation</b>	4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):  Exempt payee code (if any) <b>1</b>  Exemption from FATCA reporting code (if any) <b>A</b>  <small>(Applies to accounts maintained outside the U.S.)</small>	
5 Address (number, street, and apt. or suite no.) See instructions. <b>200 First Street SW</b>		Requester's name and address (optional)
6 City, state, and ZIP code <b>Rochester, MN 55905</b>		
7 List account number(s) here (optional)		

## Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

**Note:** If the account is in more than one name, see the instructions for line 1. Also see *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number								
			-				-	
or								
Employer identification number								
4	1	-	6	0	1	1	7	0 2

## Part II Certification

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because: (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

**Certification instructions.** You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here	Signature of U.S. person ► 	Date ► <b>01/01/21</b>
-----------	--	------------------------

## General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

**Future developments.** For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9).

## Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS must obtain your correct taxpayer identification number (TIN) which may be your social security number (SSN), individual taxpayer identification number (ITIN), adoption taxpayer identification number (ATIN), or employer identification number (EIN), to report on an information return the amount paid to you, or other amount reportable on an information return. Examples of information returns include, but are not limited to, the following.

- Form 1099-INT (interest earned or paid)

- Form 1099-DIV (dividends, including those from stocks or mutual funds)
- Form 1099-MISC (various types of income, prizes, awards, or gross proceeds)
- Form 1099-B (stock or mutual fund sales and certain other transactions by brokers)
- Form 1099-S (proceeds from real estate transactions)
- Form 1099-K (merchant card and third party network transactions)
- Form 1098 (home mortgage interest), 1098-E (student loan interest), 1098-T (tuition)
- Form 1099-C (canceled debt)
- Form 1099-A (acquisition or abandonment of secured property)

Use Form W-9 only if you are a U.S. person (including a resident alien), to provide your correct TIN.

If you do not return Form W-9 to the requester with a TIN, you might be subject to backup withholding. See What is backup withholding, later.